Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients

被引:0
作者
Ikeda, Y.
Suehiro, T.
Itahara, T.
Inui, Y.
Chikazawa, H.
Inoue, M.
arii, K.
Hashimoto, K.
机构
[1] Kochi Univ, Kochi Med Sch, Dept Endocrinol Metab & Nephrol, Nanko Ku, Kochi 7838505, Japan
[2] Tosa Municipal Hosp, Dept Internal Med, Kochi, Japan
[3] Kohoku Municipal Hosp, Dept Internal Med, Kochi, Japan
[4] Kubokawa Hosp, Dept Internal Med, Kochi, Japan
关键词
serum paraoxonase; PON1; hemodialysis; cardiovascular disease;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: Human serum paraoxonase (PON1) is associated with high-density lipoprotein, and inhibits oxidative modification of low-density lipoprotein. Therefore, PON1 is supposed to contribute to the prevention of atherosclerosis. We and other investigators have shown that the enzymatic activities and concentrations of PON1 were decreased in maintenance hemodialysis (HD) patients. However, the effect of PON1 status on the long-term outcome of HD patients has not been reported. In this study, we examined the association between baseline PON1 status and cardiovascular mortality in an observation study of an outpatient HD population. Patients and methods: The relation between baseline cardiovascular risk factors and clinical events was investigated, during 6 years of follow-up, in 81 HD patients (50 males and 31 females) whose enzymatic activities, concentrations and genetic polymorphisms of PON1 had been determined in a previous study. Results: During follow-up for 6 years, we recorded 42 deaths, including 24 fatal cardiovascular events. In univariate analyses, baseline PON1 concentration was associated with not only cardiovascular mortality (p < 0.005), but also all-cause mortality (p < 0.001) during the period of follow-up, as were age, preexisting cardiovascular disease (CVD) and hemoglobin concentration. In a multivariate Cox regression analysis, PON1 concentration retained significant associations with cardiovascular mortality (p < 0.05) and all-cause mortality (p < 0.005) even after correction of known risk factors for CVD or mortality in HD patients. Using Kaplan-Meier survival curves, we assessed the association between low and high concentrations of PON1 divided according to the median value (7.52 U/ml). Significantly increased cardiovascular mortality (log rank 6.125, p = 0.01) and all-cause mortality (log rank 7.113, p < 0.01) were detected in the patients with low PON1 concentrations. Conclusions: These data suggest that low PON1 concentration maybe an independent predictor of cardiovascular mortality in maintenance HD patients.
引用
收藏
页码:358 / 365
页数:8
相关论文
共 35 条
  • [1] ADKINS S, 1993, AM J HUM GENET, V52, P598
  • [2] Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R
    Aviram, M
    Billecke, S
    Sorenson, R
    Bisgaier, C
    Newton, R
    Rosenblat, M
    Erogul, J
    Hsu, C
    Dunlop, C
    La Du, B
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) : 1617 - 1624
  • [3] The role of oxidized lipoproteins in atherogenesis
    Berliner, JA
    Heinecke, JW
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1996, 20 (05) : 707 - 727
  • [4] Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia
    Biasioli, S
    Schiavon, R
    Petrosino, L
    De Fanti, E
    Cavalcanti, G
    Battaglia, P
    Fasolin, A
    [J]. ASAIO JOURNAL, 2003, 49 (03) : 295 - 299
  • [5] IDENTIFICATION OF A DISTINCT HUMAN HIGH-DENSITY-LIPOPROTEIN SUBSPECIES DEFINED BY A LIPOPROTEIN-ASSOCIATED PROTEIN, K-45 - IDENTITY OF K-45 WITH PARAOXONASE
    BLATTER, MC
    JAMES, RW
    MESSMER, S
    BARJA, F
    POMETTA, D
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 211 (03): : 871 - 879
  • [6] Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
    Brophy, VH
    Jarvik, GP
    Richter, RJ
    Rozek, LS
    Schellenberg, GD
    Furlong, CE
    [J]. PHARMACOGENETICS, 2000, 10 (05): : 453 - 460
  • [7] Cao HB, 1999, J LIPID RES, V40, P133
  • [8] Dantoine TF, 1998, J AM SOC NEPHROL, V9, P2082
  • [9] Dirican M, 2004, J NEPHROL, V17, P813
  • [10] Paraoxonase and atherosclerosis
    Durrington, PN
    Mackness, B
    Mackness, MI
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) : 473 - 480